Patient & Healthcare Impact | Ferring Pharmaceuticals

Patient Burden

Recurrence is a vicious cycle

Up to 35%

of patients experience recurrence^3,a

Up to 60%

of patients experience subsequent recurrences⁴

Physical and psychological suffering continues

A 2017 U.S. study that surveyed patients with C. diff or recurrent C. diff found that two-thirds of the 350 patients reported physical and psychological symptoms (63.5% and 66.1%, respectively).

41% of patients believed they would never get rid of post-C. diff symptoms
Participant quotes included:

“I panic all the time and my anxiety is through the roof.”
“…Now life as I knew it has drastically changed. Sometimes I feel I will never feel normal again.”
“There is a social stigma associated with C. diff…”
“I feel like everyone is afraid of me.”
“I lost my job of 12 years mostly because my productivity went down.”⁵

Mortality and debilitating consequences^b

C. diff can lead to significant complications including sepsis, colectomy, and mortality

Sepsis

27% of patients (aged 18 to 64 years) with one recurrence experienced sepsis during 12-months follow-up^6,c
52.5% of patients with recurrent C. diff developed sepsis at 12-months^6,c

Colectomy

7% of patients with one recurrence had a colectomy during 12-months follow-up^6,c

Mortality

6% of patients with index C. diff within 30 days of diagnosis⁷
25% of patients with recurrent C. diff at 12-months⁸

Other severe complications in patients include heart failure (43%),^9,d anxiety (14%),^10,e and depression (15%).^10,e

Healthcare Burden

Hospitalizations

Up to 40% of patients with community-associated C. diff require hospital admission²

Length of stay

Hospitalizations averaged 35 days for patients that required a hospital stay²

Average length of stay associated with C. diff was 24.8 days in Canada in 2019¹¹

C. diff associated with higher rates of mortality within 180 days of hospital discharge¹²

Costs

$281 Million in total cost to society (hospital costs, community and long-term care costs and lost productivity) for C. diff in Canada in 2012¹³

$114 – $171 Million total cost (hospital costs and lost productivity) associated with C. diff in Canada in 2019¹¹

Ferring is committed to exploring the potential of a microbiome-based therapeutic that is studied in a comprehensive population reflective of routine clinical practice for the prevention of recurrent C. diff.

^a Within 8 weeks after initial C. diff diagnosis and successful treatment.
^b Based on U.S. data
^c Longitudinal, retrospective study of the US PharMetrics Plus™ database reported on complications of recurrent C. diff over 1 year (N=46,571) from a single referral center.
^d Retrospective study of a Medicare claims analysis of patients with C. diff (N=268,762).
^e 12-month follow-up of retrospective cohort study at first recurrence (N=38,163).

References

Government of Canada website. Fact Sheet – Clostridium difficile (C. difficile). Accessed November 3, 2023, at https://www.canada.ca/en/public-health/services/infectious-diseases/fact-sheet-clostridium-difficile-difficile.html.
Pereira JA, McGeer A, Tomovici A, et al. Incidence and economic burden of Clostridioides difficile infection in Ontario: a retrospective population-based study. CMAJ Open. 2020;8(1):E16-E25.
Pépin J, Routhier S, Gagnon S, et al. Management and Outcomes of a First Recurrence of Clostridium difficile - Associated Disease in Quebec, Canada. Clin Infec Dis. 2006;42(6):758-764.
Leong C, Zelenitsky S. Treatment strategies for recurrent Clostridium difficile infection. Can J Hosp Pharm. 2013;66(6):361-368.
Lurienne L, Bandinelli PA, Galvain T, et al. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes. 2020;4(1):14.
Feuerstadt P, Boules M, Stong L, et al. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: a real-world data analysis. SAGE Open Med. 2021;14(9):1-8.
Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-834.
Feuerstadt P, Nelson WW, Drozd EM, et al. Mortality, health care use, and costs of Clostridioides difficile infections in older adults. J Am Med Dir Assoc. 2022;S1525-8610(22):00153-0.
Nelson WW, Scott TA, Boules M, et al. Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis. J Manag Care Spec Pharm. 2021;27(7):828-838.
Scott TA, Unni S, Boules M, et al. Clinical burden of recurrent Clostridioides difficile infection in the Medicare population. Presented at: 2020 Digestive Disease Week; May 2-5, 2020; Chicago, IL.
Diener A, Wang H, Nkangu, M. Hospital and related resource costs associated with antimicrobial-resistant infections in Canada, 2019. Can Commun Dis Rep. 2022;48(11/12):529-539.
Pereira JA, McGeer A, Tomovici A, et al. The Clinical Burden of Clostridioides difficile in Ontario, Canada. Open Forum Infect Dis. 2020;7(2):ofz523.
Levy AR, Szabo SM, Lorano-Ortega G, et al. Incidence and Costs of Clostridium difficile Infections in Canada. Open Forum Infect Dis. 2015;2(3):ofv076.

© 2024 Ferring. Ferring and the Ferring Pharmaceuticals logo and, unless otherwise specified, all product names and service names are trademarks owned by, or licensed to, the Ferring group of companies. All other trademarks are the property of their respective owner(s).

REDUCE THE BURDEN RECURRENT C. DIFFICILE INFECTION (C. DIFF) IS PLACING ON YOU AND YOUR PATIENTS